AmacaThera Secures Funding to Initiate Phase I Trial of Non-Opioid Pain Control Therapeutic

AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has raised $3.25 million CAD in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners. 

Click here to learn more

Previous
Previous

Apply for the SmartStart Seed Fund Program

Next
Next

Synaptive Medical Announces Partnership with Halifax's BIOTIC